GlobeNewswire Inc | Jan 5, 2021 08:00AM EST

January 05, 2021

BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event.

Panel Presentation DetailsTitle: Dermatology Innovation: Addressing Physician and Patient Underserved NeedsDay: Thursday, January 7Time: 2:00pm Eastern TimeRegistration https://wsw.com/webcast/lifesci/panel9/2316951Link: Title: Executing a Successful Product Launch During a PandemicDay: Friday, January 8Time: 2:00pm Eastern TimeRegistration https://wsw.com/webcast/lifesci/panel14/2387307Link:

The format will be a virtual presentation with the opportunity for Q&A at the conclusion.

About VYNE Therapeutics Inc.In March 2020, Menlo Therapeutics Inc. ("Menlo") and Foamix Pharmaceuticals Ltd. (Foamix) combined to form what is now known as VYNE Therapeutics Inc. VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST), and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, the worlds first topical minocycline, and for ZILXI (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for adults with the pimples and bumps of rosacea. For more information about our approved products, please see AMZEEQs Full Prescribing Information at AMZEEQ.com and ZILXIs Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit http://www.vynetherapeutics.com/ or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNEs website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

CONTACT:Joyce AllaireLifeSci Advisors, LLC646-889-1200jallaire@lifesciadvisors.com

Andrew SaikChief Financial OfficerVYNE Therapeutics908-731-6180Andrew.Saik@vynetx.com